{"id":"daclizumab","rwe":[{"pmid":"41855370","year":"2006","title":"Depemokimab.","finding":"","journal":"","studyType":"Clinical Study"},{"pmid":"41753126","year":"2026","title":"Interleukin-2 Receptor Antagonist Induction Therapy in Lung Transplantation-A Meta-Analysis of Reconstructed Time-to-Event Data.","finding":"","journal":"Journal of clinical medicine","studyType":"Clinical Study"},{"pmid":"41747595","year":"2026","title":"Single-cell transcriptomic mendelian randomization and co-localization reveal immune-mediated regulatory mechanisms and drug targets in atopic dermatitis.","finding":"","journal":"International immunopharmacology","studyType":"Clinical Study"},{"pmid":"41704136","year":"2026","title":"No Association of Sex or Racial Factors With Outcomes in Adult Intestine-Only Transplant: A United Network for Organ Sharing Database Analysis.","finding":"","journal":"Experimental and clinical transplantation : official journal of the Middle East Society for Organ Transplantation","studyType":"Clinical Study"},{"pmid":"31643690","year":"2012","title":"Multiple Sclerosis Agents.","finding":"","journal":"","studyType":"Clinical Study"}],"tags":[{"label":"Interleukin-2 Receptor Blocking Antibody","category":"class"},{"label":"Monoclonal Antibody","category":"modality"},{"label":"Interleukin-2 receptor","category":"target"},{"label":"IL2RA","category":"gene"},{"label":"IL2RB","category":"gene"},{"label":"IL2RG","category":"gene"},{"label":"L04AC01","category":"atc"},{"label":"Active","category":"status"},{"label":"Relapsing remitting multiple sclerosis","category":"indication"},{"label":"Renal transplant rejection","category":"indication"},{"label":"Hoffman-La Roche","category":"company"},{"label":"Approved 1990s","category":"decade"},{"label":"Immunologic Factors","category":"pharmacology"},{"label":"Immunosuppressive Agents","category":"pharmacology"}],"phase":"marketed","safety":{"safetySignals":[{"llr":2372.302,"date":"","count":410,"signal":"Transplant dysfunction","source":"DrugCentral FAERS","actionTaken":"Reported 410 times (LLR=2372)"},{"llr":1816.174,"date":"","count":367,"signal":"Ovarian cyst","source":"DrugCentral FAERS","actionTaken":"Reported 367 times (LLR=1816)"},{"llr":1756.176,"date":"","count":381,"signal":"Transplant rejection","source":"DrugCentral FAERS","actionTaken":"Reported 381 times (LLR=1756)"},{"llr":1530.985,"date":"","count":370,"signal":"Acne","source":"DrugCentral FAERS","actionTaken":"Reported 370 times (LLR=1531)"},{"llr":823.304,"date":"","count":424,"signal":"Alopecia","source":"DrugCentral FAERS","actionTaken":"Reported 424 times (LLR=823)"},{"llr":419.21,"date":"","count":152,"signal":"Multiple sclerosis relapse","source":"DrugCentral FAERS","actionTaken":"Reported 152 times (LLR=419)"},{"llr":389.343,"date":"","count":145,"signal":"Sleep disorder due to general medical condition, insomnia type","source":"DrugCentral FAERS","actionTaken":"Reported 145 times (LLR=389)"},{"llr":389.177,"date":"","count":157,"signal":"Liver function test abnormal","source":"DrugCentral FAERS","actionTaken":"Reported 157 times (LLR=389)"},{"llr":189.776,"date":"","count":157,"signal":"Rheumatoid arthritis","source":"DrugCentral FAERS","actionTaken":"Reported 157 times (LLR=190)"},{"llr":126.546,"date":"","count":42,"signal":"Kidney transplant rejection","source":"DrugCentral FAERS","actionTaken":"Reported 42 times (LLR=127)"},{"llr":116.408,"date":"","count":195,"signal":"Pneumonia","source":"DrugCentral FAERS","actionTaken":"Reported 195 times (LLR=116)"},{"llr":104.88,"date":"","count":79,"signal":"Loss of personal independence in daily activities","source":"DrugCentral FAERS","actionTaken":"Reported 79 times (LLR=105)"},{"llr":102.668,"date":"","count":159,"signal":"Condition aggravated","source":"DrugCentral FAERS","actionTaken":"Reported 159 times (LLR=103)"},{"llr":80.345,"date":"","count":45,"signal":"Incorrect route of product administration","source":"DrugCentral FAERS","actionTaken":"Reported 45 times (LLR=80)"},{"llr":78.663,"date":"","count":182,"signal":"Pain","source":"DrugCentral FAERS","actionTaken":"Reported 182 times (LLR=79)"}],"commonSideEffects":[]},"trials":[],"aliases":[],"company":"Hoffman-La Roche","patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=DACLIZUMAB","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T03:42:25.140673+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T03:42:31.909112+00:00"},"regulatory.eu":{"url":"","method":"api_direct","source":"European Medicines Agency","rawText":"","confidence":1,"sourceType":"ema_api","retrievedAt":"2026-04-20T03:42:25.159434+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=DACLIZUMAB","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T03:42:32.678021+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Interleukin-2 receptor inhibitor","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T03:42:33.321854+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1201605/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T03:42:33.221487+00:00"}},"allNames":"zenapax","offLabel":[],"synonyms":["zinbryta","daclizumab","zenapax"],"timeline":[{"date":"1997-12-10","type":"positive","source":"DrugCentral","milestone":"FDA approval (Hoffman-La Roche)"},{"date":"1999-02-26","type":"positive","source":"DrugCentral","milestone":"EMA approval"}],"aiSummary":"Zenapax (DACLIZUMAB) is a monoclonal antibody developed by HOFFMAN-LA ROCHE, targeting the Interleukin-2 receptor. It is classified as an Interleukin-2 Receptor Blocking Antibody, used to treat relapsing remitting multiple sclerosis and renal transplant rejection. The drug is still owned by HOFFMAN-LA ROCHE and has been FDA approved since 1997. Key safety considerations include its potential to increase the risk of infections and malignancies. Commercially, the status of Zenapax is patented.","approvals":[{"date":"1997-12-10","orphan":false,"company":"HOFFMAN-LA ROCHE","regulator":"FDA"},{"date":"1999-02-26","orphan":false,"company":"","regulator":"EMA"}],"brandName":"Zenapax","ecosystem":[{"indication":"Relapsing remitting multiple sclerosis","otherDrugs":[{"name":"alemtuzumab","slug":"alemtuzumab","company":"Genzyme"},{"name":"cladribine","slug":"cladribine","company":""},{"name":"dimethyl fumarate","slug":"dimethyl-fumarate","company":"Biogen Idec Inc"},{"name":"fingolimod","slug":"fingolimod","company":"Novartis"}],"globalPrevalence":null},{"indication":"Renal transplant rejection","otherDrugs":[{"name":"basiliximab","slug":"basiliximab","company":"Novartis"},{"name":"belatacept","slug":"belatacept","company":"Bristol Myers Squibb"},{"name":"muromonab-CD3","slug":"muromonab-cd3","company":"Ortho Biotech"},{"name":"tacrolimus","slug":"tacrolimus","company":"Astellas"}],"globalPrevalence":null}],"mechanism":{"target":"Interleukin-2 receptor","novelty":"Follow-on","targets":[{"gene":"IL2RA","source":"DrugCentral","target":"Interleukin-2 receptor","protein":"Interleukin-2 receptor subunit alpha"},{"gene":"IL2RB","source":"DrugCentral","target":"Interleukin-2 receptor","protein":"Interleukin-2 receptor subunit beta"},{"gene":"IL2RG","source":"DrugCentral","target":"Interleukin-2 receptor","protein":"Cytokine receptor common subunit gamma"}],"moaClass":"Interleukin 2 Receptor Antagonists","modality":"Monoclonal Antibody","drugClass":"Interleukin-2 Receptor Blocking Antibody","explanation":"","oneSentence":"","technicalDetail":"DACLIZUMAB is a humanized monoclonal antibody that selectively binds to the alpha subunit of the Interleukin-2 receptor, preventing the interaction with its ligand and subsequent activation of T cells."},"commercial":{"launchDate":"1997","_launchSource":"DrugCentral (FDA 1997-12-10, HOFFMAN-LA ROCHE)"},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/4953","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=DACLIZUMAB","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=DACLIZUMAB","fields":["publications"],"source":"PubMed/NCBI"}],"_emaChecked":true,"_enrichedAt":"2026-03-30T10:27:20.758732","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T03:42:35.096110+00:00","fieldsConflicting":2,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"basiliximab","drugSlug":"basiliximab","fdaApproval":"1998-05-12","relationship":"same-class"},{"drugName":"anakinra","drugSlug":"anakinra","fdaApproval":"2001-11-14","relationship":"same-class"},{"drugName":"rilonacept","drugSlug":"rilonacept","fdaApproval":"2008-02-27","relationship":"same-class"},{"drugName":"ustekinumab","drugSlug":"ustekinumab","fdaApproval":"2009-09-25","relationship":"same-class"},{"drugName":"tocilizumab","drugSlug":"tocilizumab","fdaApproval":"2010-01-08","relationship":"same-class"},{"drugName":"canakinumab","drugSlug":"canakinumab","fdaApproval":"2009-06-17","relationship":"same-class"},{"drugName":"secukinumab","drugSlug":"secukinumab","fdaApproval":"2015-01-21","relationship":"same-class"},{"drugName":"siltuximab","drugSlug":"siltuximab","fdaApproval":"2014-04-23","relationship":"same-class"},{"drugName":"brodalumab","drugSlug":"brodalumab","fdaApproval":"2017-02-15","relationship":"same-class"},{"drugName":"ixekizumab","drugSlug":"ixekizumab","fdaApproval":"2016-03-22","relationship":"same-class"},{"drugName":"sarilumab","drugSlug":"sarilumab","fdaApproval":"2017-05-22","relationship":"same-class"},{"drugName":"guselkumab","drugSlug":"guselkumab","fdaApproval":"2017-07-13","relationship":"same-class"},{"drugName":"tildrakizumab","drugSlug":"tildrakizumab","fdaApproval":"2018-03-20","relationship":"same-class"},{"drugName":"risankizumab","drugSlug":"risankizumab","fdaApproval":"2019-04-23","relationship":"same-class"},{"drugName":"satralizumab","drugSlug":"satralizumab","fdaApproval":"2020-08-14","relationship":"same-class"},{"drugName":"spesolimab","drugSlug":"spesolimab","fdaApproval":"2022-09-01","relationship":"same-class"}],"genericName":"daclizumab","indications":{"approved":[{"name":"Relapsing remitting multiple sclerosis","source":"DrugCentral","snomedId":426373005,"regulator":"FDA"},{"name":"Renal transplant rejection","source":"DrugCentral","snomedId":236570004,"regulator":"FDA"}],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"basiliximab","brandName":"basiliximab","genericName":"basiliximab","approvalYear":"1998","relationship":"same-class"},{"drugId":"anakinra","brandName":"anakinra","genericName":"anakinra","approvalYear":"2001","relationship":"same-class"},{"drugId":"rilonacept","brandName":"rilonacept","genericName":"rilonacept","approvalYear":"2008","relationship":"same-class"},{"drugId":"ustekinumab","brandName":"ustekinumab","genericName":"ustekinumab","approvalYear":"2009","relationship":"same-class"},{"drugId":"tocilizumab","brandName":"tocilizumab","genericName":"tocilizumab","approvalYear":"2010","relationship":"same-class"},{"drugId":"canakinumab","brandName":"canakinumab","genericName":"canakinumab","approvalYear":"2009","relationship":"same-class"},{"drugId":"secukinumab","brandName":"secukinumab","genericName":"secukinumab","approvalYear":"2015","relationship":"same-class"},{"drugId":"siltuximab","brandName":"siltuximab","genericName":"siltuximab","approvalYear":"2014","relationship":"same-class"},{"drugId":"brodalumab","brandName":"brodalumab","genericName":"brodalumab","approvalYear":"2017","relationship":"same-class"},{"drugId":"ixekizumab","brandName":"ixekizumab","genericName":"ixekizumab","approvalYear":"2016","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT00706420","phase":"PHASE1","title":"Islet Transplantation Alone (ITA) in Patients With Difficult to Control Type I Diabetes Mellitus Using a Glucocorticoid-free Immunosuppressive Regimen","status":"ACTIVE_NOT_RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2004-04-07","conditions":["Diabetes Mellitus"],"enrollment":17,"completionDate":"2026-10-12"},{"nctId":"NCT04472975","phase":"","title":"Prescription Drug Safety and Effectiveness in Multiple Sclerosis","status":"COMPLETED","sponsor":"University of British Columbia","startDate":"1996-01-01","conditions":["Multiple Sclerosis"],"enrollment":35000,"completionDate":"2018-03-31"},{"nctId":"NCT00321555","phase":"PHASE2","title":"LMB-2 to Treat Hairy Cell Leukemia","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2006-05-02","conditions":["Hairy Cell Leukemia"],"enrollment":15,"completionDate":"2022-12-31"},{"nctId":"NCT00685061","phase":"PHASE4","title":"Thymoglobulin Versus Campath-1H Versus Daclizumab in Adult, Primary Deceased Donor Renal Transplantation","status":"COMPLETED","sponsor":"University of Miami","startDate":"2002-11","conditions":["Renal Transplantation"],"enrollment":90,"completionDate":"2005-09"},{"nctId":"NCT01172418","phase":"PHASE4","title":"Randomized Trial of 2 Antibody Induction Steroid Avoidance Protocols","status":"COMPLETED","sponsor":"University of Miami","startDate":"2006-02","conditions":["Transplant; Failure, Kidney"],"enrollment":200,"completionDate":"2010-05"},{"nctId":"NCT00681343","phase":"PHASE4","title":"Thymoglobulin Versus Campath-1H Versus Daclizumab in Adult, Primary Living Donor Renal Transplantation","status":"COMPLETED","sponsor":"University of Miami","startDate":"2002-09","conditions":["Living-Donor Kidney Transplant"],"enrollment":38,"completionDate":"2007-10"},{"nctId":"NCT00579527","phase":"PHASE1,PHASE2","title":"Phase I/II Thymus Transplantation With Immunosuppression #950","status":"COMPLETED","sponsor":"Sumitomo Pharma Switzerland GmbH","startDate":"2005-12-19","conditions":["DiGeorge Anomaly","Complete DiGeorge Anomaly","Complete Atypical DiGeorge Anomaly","Complete DiGeorge Syndrome","Complete Atypical DiGeorge Syndrome"],"enrollment":14,"completionDate":"2017-12-31"},{"nctId":"NCT01468311","phase":"PHASE1,PHASE2","title":"Yttrium-90-labeled Daclizumab With Chemotherapy and Stem Cell Transplant for Hodgkin's Lymphoma","status":"TERMINATED","sponsor":"National Cancer Institute (NCI)","startDate":"2011-10-11","conditions":["Hodgkin Disease","Hodgkin Lymphoma"],"enrollment":6,"completionDate":"2020-10-22"},{"nctId":"NCT00246129","phase":"PHASE4","title":"CamTac Trial:Campath-Tacrolimus vs IL2R MoAb/Tacrolimus/MMF in Renal Transplantation","status":"COMPLETED","sponsor":"EMagnusson","startDate":"2005-10","conditions":["Kidney Transplantation","Kidney Diseases","Kidney Failure"],"enrollment":123,"completionDate":"2011-06"},{"nctId":"NCT00789308","phase":"PHASE2","title":"Safety and Effectiveness of Low Molecular Weight Sulfated Dextran in Islet Transplantation","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2008-07-11","conditions":["Diabetes Mellitus, Type I"],"enrollment":24,"completionDate":"2014-08-21"},{"nctId":"NCT00001962","phase":"PHASE2","title":"A Study to Determine Whether Therapy With Daclizumab Will Benefit Patients With Bone Marrow Failure","status":"TERMINATED","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"1999-11","conditions":["Aplastic Anemia","Pure Red Cell Aplasia","Diamond Blackfan Anemia"],"enrollment":100,"completionDate":"2010-09"},{"nctId":"NCT00566813","phase":"PHASE1,PHASE2","title":"Islet Transplantation in Type 1 Diabetic Patients Using the Edmonton Protocol of Steroid Free Immunosuppression","status":"COMPLETED","sponsor":"University of Illinois at Chicago","startDate":"2004-11","conditions":["Diabetes Mellitus, Type 1"],"enrollment":10,"completionDate":"2020-07-15"},{"nctId":"NCT00198146","phase":"PHASE2","title":"Prevention of Diabetes Progression Trial (PDPT)","status":"COMPLETED","sponsor":"Indiana University School of Medicine","startDate":"2000-07","conditions":["Newly Diagnosed With Type 1 Diabetes"],"enrollment":40,"completionDate":"2007-02-23"},{"nctId":"NCT00100178","phase":"PHASE2","title":"New Onset of Type 1 Diabetes Mycophenolate Mofetil-Daclizumab Clinical Trial","status":"COMPLETED","sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","startDate":"2004-05","conditions":["Diabetes Mellitus, Type 1"],"enrollment":126,"completionDate":"2008-04"},{"nctId":"NCT02411084","phase":"PHASE3","title":"Study of BEGEDINA® vs \"Conventional Treatment\" for Treating Steroid-Resistant Acute GvHD","status":"TERMINATED","sponsor":"Adienne SA","startDate":"2016-02","conditions":["Graft vs Host Disease"],"enrollment":36,"completionDate":"2017-07-31"},{"nctId":"NCT01797965","phase":"PHASE3","title":"Long-Term Extension Study in Participants With Multiple Sclerosis Who Have Completed Study 205MS301 (NCT01064401) to Evaluate the Safety and Efficacy of BIIB019","status":"TERMINATED","sponsor":"Biogen","startDate":"2013-02-15","conditions":["Relapsing-Remitting Multiple Sclerosis","Multiple Sclerosis"],"enrollment":1501,"completionDate":"2018-09-24"},{"nctId":"NCT00006350","phase":"PHASE2","title":"Mycophenolate Mofetil, Tacrolimus, Daclizumab, and Donor Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer","status":"COMPLETED","sponsor":"University of Maryland, Baltimore","startDate":"2000-01","conditions":["Leukemia","Lymphoma","Multiple Myeloma and Plasma Cell Neoplasm","Myelodysplastic Syndromes"],"enrollment":0,"completionDate":"2001-11"},{"nctId":"NCT01143441","phase":"PHASE1","title":"Investigating Mechanism of Action of DAC HYP in the Treatment of High-Inflammatory Multiple Sclerosis (MS)","status":"COMPLETED","sponsor":"National Institute of Neurological Disorders and Stroke (NINDS)","startDate":"2010-05-13","conditions":["Multiple Sclerosis","Multiple Sclerosis, Relapsing-Remitting"],"enrollment":48,"completionDate":"2017-08-11"},{"nctId":"NCT02881567","phase":"PHASE3","title":"Efficacy and Safety of Daclizumab in Participants With RRMS Switching From Natalizumab","status":"TERMINATED","sponsor":"Biogen","startDate":"2017-04-18","conditions":["Relapsing-Remitting Multiple Sclerosis (RRMS)"],"enrollment":41,"completionDate":"2018-09-12"},{"nctId":"NCT01051349","phase":"PHASE2","title":"Safety and Efficacy Extension Study of Daclizumab High Yield Process (DAC HYP) (BIIB019) in Participants Who Have Completed Study 205MS202 (NCT00870740) to Treat Relapsing Remitting Multiple Sclerosis","status":"COMPLETED","sponsor":"Biogen","startDate":"2010-03-31","conditions":["Relapsing-Remitting Multiple Sclerosis"],"enrollment":410,"completionDate":"2016-08-25"},{"nctId":"NCT01132014","phase":"EARLY_PHASE1","title":"Autologous OC-DC Vaccine in Ovarian Cancer","status":"COMPLETED","sponsor":"Abramson Cancer Center at Penn Medicine","startDate":"2010-05","conditions":["Chemotherapy","Tumor","Ovarian Cancer"],"enrollment":67,"completionDate":"2018-05-30"},{"nctId":"NCT00080535","phase":"PHASE2","title":"Anti-Tac(Fv)-PE38 (LMB-2) to Treat Cutaneous T-Cell Lymphomas","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2004-04-30","conditions":["Lymphoma","T-Cell","Cutaneous"],"enrollment":10,"completionDate":"2011-12-31"},{"nctId":"NCT00077922","phase":"PHASE2","title":"Anti-Tac(Fv)-PE38 (LMB-2) to Treat Chronic Lymphocytic Leukemia","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2004-02-29","conditions":["Leukemia","Lymphocytic","Chronic"],"enrollment":15,"completionDate":"2011-12-31"},{"nctId":"NCT00275509","phase":"PHASE3","title":"Induction Therapy Study in Live Donor Kidney Transplant Recipients With a Positive Crossmatch","status":"COMPLETED","sponsor":"Johns Hopkins University","startDate":"2007-01","conditions":["Kidney Failure, Chronic"],"enrollment":56,"completionDate":"2010-06"},{"nctId":"NCT00181142","phase":"PHASE2,PHASE3","title":"The Use of Daclizumab and Anti-Thymocyte Globulin in Lung Transplantation","status":"COMPLETED","sponsor":"Johns Hopkins University","startDate":"1999-10","conditions":["Patients Active and Listed for Lung Transplantation"],"enrollment":60,"completionDate":"2004-12"},{"nctId":"NCT00468117","phase":"PHASE3","title":"Efficacy of Islet After Kidney Transplantation","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2007-01","conditions":["Type 1 Diabetes Mellitus"],"enrollment":24,"completionDate":"2017-07-05"},{"nctId":"NCT00533442","phase":"PHASE2","title":"Rapamycin Versus Mycophenolate Mofetil in Kidney-Pancreas Recipients","status":"COMPLETED","sponsor":"University of Miami","startDate":"2000-09","conditions":["Type 1 Diabetes"],"enrollment":170,"completionDate":"2016-05"},{"nctId":"NCT00078689","phase":"PHASE1","title":"Daclizumab and Sirolimus to Treat Uveitis","status":"COMPLETED","sponsor":"National Eye Institute (NEI)","startDate":"2004-03-03","conditions":["Uveitis"],"enrollment":6,"completionDate":"2008-07-18"},{"nctId":"NCT00071838","phase":"PHASE2","title":"Zenapax (Daclizumab) to Treat Relapsing Remitting Multiple Sclerosis","status":"COMPLETED","sponsor":"National Institute of Neurological Disorders and Stroke (NINDS)","startDate":"2003-10-30","conditions":["Multiple Sclerosis, Relapsing-Remitting"],"enrollment":16,"completionDate":"2011-08-16"},{"nctId":"NCT00070759","phase":"PHASE2","title":"Daclizumab to Treat Non-Infectious Sight-Threatening Uveitis","status":"COMPLETED","sponsor":"National Eye Institute (NEI)","startDate":"2003-10-06","conditions":["Uveitis"],"enrollment":6,"completionDate":"2006-10-02"},{"nctId":"NCT00080431","phase":"PHASE1","title":"Daclizumab to Treat HIV-Infected Patients","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2004-03-26","conditions":["HIV Infections"],"enrollment":10,"completionDate":"2007-12-28"},{"nctId":"NCT00326508","phase":"PHASE2","title":"Combination Daclizumab/Denileukin Diftitox to Treat Uveitis","status":"COMPLETED","sponsor":"National Eye Institute (NEI)","startDate":"2006-05-11","conditions":["Non-infectious Intermediate and Posterior Uveitis"],"enrollment":5,"completionDate":"2006-12-20"},{"nctId":"NCT00001526","phase":"PHASE1","title":"ANTI-TAC THERAPY FOR UVEITIS","status":"COMPLETED","sponsor":"National Eye Institute (NEI)","startDate":"1996-06-04","conditions":["Uveitis"],"enrollment":15,"completionDate":"2007-09-06"},{"nctId":"NCT00357266","phase":"","title":"Differences in Genes and Proteins in Active and Controlled Uveitis","status":"COMPLETED","sponsor":"National Eye Institute (NEI)","startDate":"2002-02-01","conditions":["Ocular Inflammatory Disease","Uveitis"],"enrollment":60,"completionDate":"2007-10-24"},{"nctId":"NCT00014911","phase":"PHASE2","title":"Islet Transplantation for Type 1 Diabetes","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2001-04","conditions":["Diabetes Mellitus, Insulin-Dependent"],"enrollment":36,"completionDate":"2010-08"},{"nctId":"NCT01462318","phase":"PHASE3","title":"An Open-Label Immunogenicity and Pharmacokinetics Study of Daclizumab High Yield Process Prefilled Syringe in Relapsing Remitting Multiple Sclerosis","status":"COMPLETED","sponsor":"Biogen","startDate":"2011-11","conditions":["Relapsing-Remitting Multiple Sclerosis"],"enrollment":133,"completionDate":"2016-01"},{"nctId":"NCT00574470","phase":"PHASE4","title":"Anti Cytokine Combination Therapy With Daclizumab and Infliximab for Treatment of Steroid Refractory Acute GVHD","status":"COMPLETED","sponsor":"University of Iowa","startDate":"2006-01","conditions":["Graft vs Host Disease"],"enrollment":3,"completionDate":"2008-08"},{"nctId":"NCT00130637","phase":"PHASE2","title":"Human Anti-Tac (Daclizumab) to Treat Juvenile Idiopathic Arthritis (JIA)-Associated Uveitis","status":"COMPLETED","sponsor":"National Eye Institute (NEI)","startDate":"2005-08","conditions":["Anterior Uveitis","Arthritis, Juvenile Idiopathic","Iritis","Immunosuppression"],"enrollment":6,"completionDate":"2008-05"},{"nctId":"NCT00053976","phase":"PHASE3","title":"Methylprednisolone With or Without Daclizumab in Treating Patients With Acute Graft-Versus-Host Disease","status":"COMPLETED","sponsor":"Dana-Farber Cancer Institute","startDate":"2001-01","conditions":["Graft Versus Host Disease"],"enrollment":105,"completionDate":"2004-11"},{"nctId":"NCT00163657","phase":"PHASE4","title":"Study of Liver Transplant For End-Stage Liver Disease Caused By Chronic Hepatitis C Infection","status":"COMPLETED","sponsor":"Baylor Research Institute","startDate":"2002-07","conditions":["End Stage Liver Disease","Hepatitis C"],"enrollment":312,"completionDate":"2007-01"},{"nctId":"NCT00141037","phase":"PHASE1,PHASE2","title":"Steroid-Free Versus Steroid-Based Immunosuppression in Pediatric Renal (Kidney) Transplantation","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2004-03","conditions":["Kidney Diseases","Kidney Transplantation","Kidney Transplant","Renal Transplantation","Renal Transplant"],"enrollment":130,"completionDate":"2010-11"},{"nctId":"NCT00304954","phase":"PHASE2","title":"Infliximab, Sirolimus and Daclizumab to Treat Age-Related Macular Degeneration","status":"COMPLETED","sponsor":"National Eye Institute (NEI)","startDate":"2006-02","conditions":["Age-Related Macular Degeneration","Choroidal Neovascularization"],"enrollment":13,"completionDate":"2010-01"},{"nctId":"NCT00132691","phase":"PHASE4","title":"Multicenter Uveitis Steroid Treatment (MUST) Trial","status":"COMPLETED","sponsor":"JHSPH Center for Clinical Trials","startDate":"2005-09","conditions":["Uveitis"],"enrollment":255,"completionDate":"2010-12"},{"nctId":"NCT00048152","phase":"PHASE3","title":"A Study to Assess Use of Zenapax (Daclizumab) and CellCept (Mycophenolate Mofetil) to Improve Kidney Function in Kidney Transplant Patients","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2000-12","conditions":["Kidney Transplantation"],"enrollment":539,"completionDate":"2006-03"},{"nctId":"NCT02554955","phase":"PHASE4","title":"A Study of Daclizumab (Zenapax) in Combination With Mycophenolate Mofetil (CellCept) and Sirolimus in Prevention of Acute Rejection in Heart Transplant Participants","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2004-02","conditions":["Heart Transplantation"],"enrollment":36,"completionDate":"2007-12"},{"nctId":"NCT01307618","phase":"PHASE2","title":"Vaccine Therapy With or Without Recombinant Interleukin-12 Followed by Daclizumab in Treating Patients With Metastatic Melanoma","status":"TERMINATED","sponsor":"National Cancer Institute (NCI)","startDate":"2011-02","conditions":["Recurrent Melanoma","Stage IV Skin Melanoma"],"enrollment":10,"completionDate":"2015-02"},{"nctId":"NCT00203281","phase":"","title":"Study to Evaluate the Amount of Medications That May be Removed From the Body During Plasmapheresis","status":"WITHDRAWN","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University","startDate":"2003-02","conditions":["Kidney Transplantation","Plasmapheresis"],"enrollment":0,"completionDate":"2009-09"},{"nctId":"NCT00023231","phase":"NA","title":"Pediatric Kidney Transplant Without Calcineurin Inhibitors","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2001-02","conditions":["End-Stage Renal Disease"],"enrollment":35,"completionDate":"2006-08"},{"nctId":"NCT00573495","phase":"PHASE1","title":"Multipeptide Vaccine for Advanced Breast Cancer","status":"COMPLETED","sponsor":"University of Pennsylvania","startDate":"2007-11","conditions":["Breast Neoplasm","Breast Cancer","Cancer of the Breast","Carcinoma, Ductal"],"enrollment":11,"completionDate":"2013-02"},{"nctId":"NCT00870740","phase":"PHASE2","title":"Safety and Efficacy Extension Study of Daclizumab High Yield Process (DAC HYP) in Participants With Multiple Sclerosis Who Have Completed Study 205MS201 (NCT00390221) to Treat Relapsing-Remitting Multiple Sclerosis","status":"COMPLETED","sponsor":"Biogen","startDate":"2009-02","conditions":["Relapsing-Remitting Multiple Sclerosis"],"enrollment":517,"completionDate":"2012-10"},{"nctId":"NCT00390221","phase":"PHASE2","title":"Safety and Efficacy Study of Daclizumab High Yield Process (DAC HYP) to Treat Relapsing-Remitting Multiple Sclerosis","status":"COMPLETED","sponsor":"Biogen","startDate":"2008-02","conditions":["Relapsing-Remitting Multiple Sclerosis"],"enrollment":621,"completionDate":"2011-08"},{"nctId":"NCT01064401","phase":"PHASE3","title":"Efficacy and Safety of BIIB019 (Daclizumab High Yield Process) Versus Interferon β 1a in Participants With Relapsing-Remitting Multiple Sclerosis","status":"COMPLETED","sponsor":"Biogen","startDate":"2010-05","conditions":["Relapsing-Remitting Multiple Sclerosis"],"enrollment":1841,"completionDate":"2014-07"},{"nctId":"NCT00048165","phase":"PHASE4","title":"A Study to Evaluate the Efficacy and Safety of Zenapax in Combination With CellCept, Cyclosporine, and Corticosteroids in Patients Undergoing Cardiac Transplantation","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"1999-08","conditions":["Heart Transplantation"],"enrollment":434,"completionDate":"2002-08"},{"nctId":"NCT00859131","phase":"NA","title":"Safety and Efficacy Study of Thymoglobulin Versus IL2 Receptor Antagonists","status":"COMPLETED","sponsor":"Medical University of South Carolina","startDate":"2009-03","conditions":["End Stage Renal Disease"],"enrollment":200,"completionDate":"2014-07"},{"nctId":"NCT02694770","phase":"PHASE2","title":"A Study Evaluating the Efficacy and Safety of Neihulizumab vs \"Conventional Treatment\" to Treat Sr-aGvHD","status":"WITHDRAWN","sponsor":"AbGenomics B.V Taiwan Branch","startDate":"2016-07","conditions":["Steroid-refractory aGvHD Subsequent to Allogeneic Hematopoietic Cell Transplantation"],"enrollment":0,"completionDate":"2018-02"},{"nctId":"NCT00468442","phase":"PHASE2","title":"B-Lymphocyte Immunotherapy in Islet Transplantation","status":"TERMINATED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2006-11","conditions":["Type 1 Diabetes Mellitus"],"enrollment":2,"completionDate":"2011-09"},{"nctId":"NCT00434850","phase":"PHASE2","title":"Peritransplant Deoxyspergualin in Islet Transplantation in Type 1 Diabetes","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2006-10","conditions":["Diabetes Mellitus, Type 1"],"enrollment":14,"completionDate":"2013-11"},{"nctId":"NCT02686619","phase":"PHASE3","title":"Study Comparing Efficacy and Safety of Mycophenolate Mofetil (Cellcept) With Delayed Introduction of Sirolimus and Discontinuation of Cyclosporine, With Those of Mycophenolate Mofetil and Long Term Continuation of Cyclosporine in Renal Transplant Recipients","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2004-11","conditions":["Renal Transplantation"],"enrollment":237,"completionDate":"2011-01"},{"nctId":"NCT00626015","phase":"PHASE1","title":"Chemotherapy, Radiation Therapy, and Vaccine Therapy With Basiliximab in Treating Patients With Glioblastoma Multiforme That Has Been Removed by Surgery","status":"COMPLETED","sponsor":"John Sampson","startDate":"2007-03","conditions":["Malignant Neoplasms of Brain"],"enrollment":16,"completionDate":"2013-02"},{"nctId":"NCT02576145","phase":"PHASE4","title":"A Study to Assess Immune Response in Pediatric Kidney Transplant Recipients Treated With Daclizumab (Zenapax)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2003-04","conditions":["Kidney Transplantation"],"enrollment":11,"completionDate":"2006-01"},{"nctId":"NCT00001575","phase":"PHASE1,PHASE2","title":"Anti-Tac(90 Y-HAT) to Treat Hodgkin's Disease, Non-Hodgkin's Lymphoma and Lymphoid Leukemia","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"1997-04","conditions":["Hodgkin's Disease","Lymphoma, Non-Hodgkin"],"enrollment":87,"completionDate":"2013-11"},{"nctId":"NCT00284531","phase":"PHASE1,PHASE2","title":"Use of Daclizumab for the Prevention of Allograft Rejection in Pediatric Heart Transplant Patients","status":"TERMINATED","sponsor":"Baylor College of Medicine","startDate":"2003-10","conditions":["Cardiac Transplantation"],"enrollment":1,"completionDate":"2007-05"},{"nctId":"NCT00296348","phase":"PHASE3","title":"Comparing Efficacy and Safety of Steroid Withdrawal With Tacrolimus and MMF With Induction in Children After Kidney Transplantation","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2005-11","conditions":["Kidney Transplantation"],"enrollment":198,"completionDate":"2008-02"},{"nctId":"NCT00002765","phase":"PHASE1","title":"Immunotoxin in Treating Patients With Leukemia or Lymphoma","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"1996-04","conditions":["Leukemia","Lymphoma"],"enrollment":0,"completionDate":""},{"nctId":"NCT00064714","phase":"PHASE2","title":"Effect of AC2993 With or Without Immunosuppression on Beta Cell Function in Patients With Type I Diabetes","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2003-07","conditions":["Diabetes Mellitus"],"enrollment":47,"completionDate":"2008-03"},{"nctId":"NCT00321074","phase":"PHASE3","title":"Tacrolimus and Daclizumab Versus Tacrolimus and Steroids in Liver Recipients Receiving Sub-optimal Grafts","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2005-05","conditions":["LIVER TRANSPLANTATION"],"enrollment":101,"completionDate":"2007-10"},{"nctId":"NCT00295594","phase":"PHASE3","title":"Comparing Efficacy & Safety of Tacrolimus With/Without MMF or Monoclonal Anti-IL2R Antibody in Liver Transplantation.","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2005-03","conditions":["Liver Transplantation"],"enrollment":627,"completionDate":"2007-06"},{"nctId":"NCT00693524","phase":"PHASE2","title":"Sequential Therapy (FK506 + Monoclonal Anti-IL2R Antibodies + MMF) Versus FK506 With Steroids in Liver TX","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2002-11","conditions":["Liver Transplantation"],"enrollment":94,"completionDate":"2004-03"},{"nctId":"NCT00790439","phase":"PHASE2","title":"Safety and Effectiveness of Low Molecular Weight Sulfated Dextran in Islet Transplantation After Kidney Transplant","status":"WITHDRAWN","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2008-07","conditions":["Diabetes Mellitus, Type I"],"enrollment":0,"completionDate":"2009-10"},{"nctId":"NCT01929746","phase":"PHASE1","title":"Daclizumab Japanese PK Study","status":"COMPLETED","sponsor":"Biogen","startDate":"2013-10","conditions":["Healthy"],"enrollment":56,"completionDate":"2014-03"},{"nctId":"NCT00363116","phase":"PHASE4","title":"A Trial of Two Daclizumab Dosing Strategies vs. No Induction Treatment With Tacrolimus, Mycophenolate Mofetil , & Steroids for the Prevention of Acute Allograft Rejection in Simultaneous Kidney/Pancreas Transplant Recipients","status":"COMPLETED","sponsor":"University of Cincinnati","startDate":"1999-04","conditions":["Acute Allograft Rejection in Simultaneous Kidney/Pancreas Transplant Recipients"],"enrollment":298,"completionDate":"2004-12"},{"nctId":"NCT00019227","phase":"PHASE1,PHASE2","title":"Monoclonal Antibody Therapy in Treating Patients With Leukemia","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"1996-10","conditions":["Lymphoma","Radiation Toxicity"],"enrollment":0,"completionDate":"2006-07"},{"nctId":"NCT00001941","phase":"PHASE1,PHASE2","title":"Anti-Tac for Treatment of Leukemia","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"1999-12","conditions":["HTLV-I Infection","T Cell Leukemia"],"enrollment":34,"completionDate":"2011-02"},{"nctId":"NCT00285233","phase":"PHASE1,PHASE2","title":"Delayed Mycophenolate Mofetil in Single-Donor Islet Allotransplantation in Type 1 Diabetes","status":"COMPLETED","sponsor":"University of Minnesota","startDate":"2000-09","conditions":["Type 1 Diabetes","Hypoglycemia"],"enrollment":8,"completionDate":"2005-03"},{"nctId":"NCT00446264","phase":"PHASE2","title":"Islet Allotransplantation With Steroid Free Immunosuppression","status":"COMPLETED","sponsor":"University Hospital, Lille","startDate":"2003-05","conditions":["Type 1 Diabetes","Hypoglycemia","Metabolic Diseases"],"enrollment":14,"completionDate":"2009-02"},{"nctId":"NCT00389506","phase":"NA","title":"Fludarabine and Cyclophosphamide Followed By LMB-2 Immunotoxin in Treating Patients With Hodgkin's Lymphoma","status":"WITHDRAWN","sponsor":"National Institutes of Health Clinical Center (CC)","startDate":"2006-09","conditions":["Lymphoma"],"enrollment":0,"completionDate":"2008-05"},{"nctId":"NCT00028288","phase":"PHASE2","title":"Study of Daclizumab in Patients With Chronic, Persistent Asthma","status":"COMPLETED","sponsor":"Facet Biotech","startDate":"2001-09","conditions":["Asthma"],"enrollment":120,"completionDate":"2003-12"},{"nctId":"NCT00486057","phase":"","title":"Daclizumab Experience in Pediatric Heart Transplant","status":"TERMINATED","sponsor":"Children's Healthcare of Atlanta","startDate":"2004-08","conditions":["Congenital Disorders"],"enrollment":30,"completionDate":"2007-11"},{"nctId":"NCT01418430","phase":"PHASE4","title":"Pilot Study of Combination Therapy With CHOP-Zenapax (CHOP-daclizumab)","status":"COMPLETED","sponsor":"King's College Hospital NHS Trust","startDate":"","conditions":["HTLV-I Associated Adult T-cell Leukaemia/Lymphoma (ATLL)"],"enrollment":0,"completionDate":""},{"nctId":"NCT00001934","phase":"PHASE2","title":"Zenapax to Treat Multiple Sclerosis","status":"COMPLETED","sponsor":"National Institute of Neurological Disorders and Stroke (NINDS)","startDate":"1999-09","conditions":["Multiple Sclerosis"],"enrollment":22,"completionDate":"2008-09"},{"nctId":"NCT00002681","phase":"PHASE1,PHASE2","title":"Monoclonal Antibody Plus Interleukin-2 in Treating Patients With Leukemia or Lymphoma","status":"COMPLETED","sponsor":"Roger Williams Medical Center","startDate":"1995-07","conditions":["Leukemia","Lymphoma"],"enrollment":25,"completionDate":"2003-12"},{"nctId":"NCT00195273","phase":"PHASE3","title":"Study Evaluating Sirolimus in Kidney Transplant Recipients","status":"COMPLETED","sponsor":"Wyeth is now a wholly owned subsidiary of Pfizer","startDate":"2004-11","conditions":["Graft vs Host Disease","Kidney Transplantation"],"enrollment":61,"completionDate":"2008-07"},{"nctId":"NCT01046955","phase":"PHASE4","title":"Thymoglobulin Versus Alemtuzumab Versus Daclizumab in Living Donor Renal Transplantation","status":"COMPLETED","sponsor":"University of Miami","startDate":"2005-11","conditions":["End-Stage Renal Disease","Living Donors"],"enrollment":38,"completionDate":"2008-12"},{"nctId":"NCT00073047","phase":"PHASE2","title":"Humanized Anti-IL-2 Receptor Monoclonal Antibody in Moderate-to-severe Ulcerative Colitis","status":"COMPLETED","sponsor":"Facet Biotech","startDate":"2003-04","conditions":["Ulcerative Colitis","Gastrointestinal Disease","Inflammatory Bowel Disease"],"enrollment":150,"completionDate":"2006-07"},{"nctId":"NCT00050661","phase":"PHASE1,PHASE2","title":"To Study the Use of Humanized CD25 in Preventing the Relapse of Psoriasis Vulgaris","status":"COMPLETED","sponsor":"Rockefeller University","startDate":"1997-10","conditions":["Psoriasis"],"enrollment":6,"completionDate":"2008-04"},{"nctId":"NCT00050648","phase":"PHASE1,PHASE2","title":"To Study the Effects of CD25 and Low Dose Cyclosporin in the Treatment of Active Psoriasis Vulgaris","status":"COMPLETED","sponsor":"Rockefeller University","startDate":"1997-10","conditions":["Psoriasis"],"enrollment":20,"completionDate":"2008-04"},{"nctId":"NCT00847106","phase":"PHASE1,PHASE2","title":"Augmentation of Dendritic Cell-Based Vaccines in Melanoma Patients by Depletion of Regulatory T Cells in Stage IV Melanoma Patients","status":"COMPLETED","sponsor":"Radboud University Medical Center","startDate":"2004-03","conditions":["Melanoma"],"enrollment":15,"completionDate":"2005-10"},{"nctId":"NCT00493194","phase":"PHASE4","title":"Fibrosis in Renal Allografts","status":"UNKNOWN","sponsor":"University Hospital, Antwerp","startDate":"2005-05","conditions":["Kidney Failure, Chronic","Transplantation","Immunosuppression","Interstitial Fibrosis"],"enrollment":100,"completionDate":"2007-07"},{"nctId":"NCT00109161","phase":"PHASE2","title":"Study of Subcutaneous Daclizumab in Patients With Active, Relapsing Forms of Multiple Sclerosis","status":"COMPLETED","sponsor":"PDL BioPharma, Inc.","startDate":"2005-04","conditions":["Multiple Sclerosis"],"enrollment":270,"completionDate":"2006-10"},{"nctId":"NCT00682292","phase":"PHASE3","title":"Daclizumab Versus Thymoglobulin in Renal Transplant Recipients With High Immunological Risk","status":"COMPLETED","sponsor":"University Hospital, Lille","startDate":"2001-05","conditions":["Renal Transplantation"],"enrollment":227,"completionDate":"2006-11"},{"nctId":"NCT00231764","phase":"PHASE4","title":"MMF, Daclizumab and Corticosteroids as Mainstay Immunosuppression in Renal Transplant Patients","status":"COMPLETED","sponsor":"Ekberg, Henrik, M.D.","startDate":"2002-11","conditions":["Kidney Transplantation"],"enrollment":1760,"completionDate":"2008-02"},{"nctId":"NCT00049725","phase":"PHASE2","title":"Daclizumab to Treat Chronic Immune Thrombocytopenia","status":"COMPLETED","sponsor":"National Institutes of Health Clinical Center (CC)","startDate":"2002-11","conditions":["Thrombocytopenia"],"enrollment":24,"completionDate":"2004-12"},{"nctId":"NCT00001249","phase":"PHASE1","title":"Treatment of Tac-Expressing Cutaneous T-Cell Lymphoma (CTCL) and Adult T-Cell Leukemia (ATL) With Yttrium-90 Radiolabeled Anti-Tac","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"1989-12","conditions":["Leukemia, T-Cell","Lymphoma, T-Cell, Cutaneous"],"enrollment":30,"completionDate":"2000-10"},{"nctId":"NCT00040248","phase":"PHASE2","title":"Daclizumab to Treat Wegener's Granulomatosis","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2002-06","conditions":["Wegener's Granulomatosis"],"enrollment":75,"completionDate":"2005-05"},{"nctId":"NCT00072969","phase":"PHASE2","title":"A Randomized Trial of Recombinant Humanized Anti-IL-2 Receptor Antibody (Daclizumab) Versus Antithymocyte Globulin (ATG) to Treat the Cytopenia of Myelodysplastic Syndrome (MDS)","status":"COMPLETED","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"2003-11","conditions":["Myelodysplastic Syndromes"],"enrollment":132,"completionDate":"2005-08"},{"nctId":"NCT00001865","phase":"PHASE2","title":"HAT in Eye Complications of Behcet's Disease","status":"COMPLETED","sponsor":"National Eye Institute (NEI)","startDate":"1999-07","conditions":["Behcet's Syndrome","Retinal Disease","Uveitis"],"enrollment":26,"completionDate":"2004-06"},{"nctId":"NCT00043667","phase":"PHASE2","title":"Daclizumab Injections to Treat Non-Infectious Sight-Threatening Uveitis","status":"COMPLETED","sponsor":"National Eye Institute (NEI)","startDate":"2002-08","conditions":["Uveitis"],"enrollment":15,"completionDate":"2004-10"},{"nctId":"NCT00290069","phase":"PHASE4","title":"Renal Function Optimization With Mycophenolate Mofetil (MMF) Immunosuppressor Regimes (ALHAMBRA)","status":"UNKNOWN","sponsor":"Sociedad Andaluza de Trasplantes de Organos y Tejidos","startDate":"","conditions":["Kidney Diseases","Graft Rejection"],"enrollment":94,"completionDate":""},{"nctId":"NCT00138970","phase":"PHASE4","title":"Calcineurin Inhibitor-Free Immunosuppression in Renal Transplant Recipients at Low Immunogenic Risk","status":"COMPLETED","sponsor":"University of Oslo School of Pharmacy","startDate":"2002-01","conditions":["Renal Transplant Recipients"],"enrollment":70,"completionDate":"2005-02"}],"_emaApprovals":[{"date":"1999-02-26","status":"Authorised","company":""}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"NUI":"N0000148541","MMSL":"11508","NDDF":"007284","UNII":"CUJ2MVI71Y","VUID":"4021083","VANDF":"4021083","INN_ID":"7164","RXNORM":"1795335","UMLSCUI":"C0663182","chemblId":"CHEMBL1201605","ChEMBL_ID":"CHEMBL1201605","KEGG_DRUG":"D03639","DRUGBANK_ID":"DB00111","SNOMEDCT_US":"109133001","IUPHAR_LIGAND_ID":"6880","MESH_DESCRIPTOR_UI":"D000077561"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[{"period":"1997-","companyName":"Hoffman-La Roche","relationship":"Original Developer"}],"publicationCount":1021,"therapeuticAreas":["Immunology"],"_revenueScrapedAt":"2026-03-31 12:31:30.94047+00","atcClassification":{"source":"DrugCentral","atcCode":"L04AC01","allCodes":["L04AC01"]},"biosimilarFilings":[],"originalDeveloper":"Hoffman-La Roche","recentPublications":[{"date":"2006","pmid":"41855370","title":"Depemokimab.","journal":""},{"date":"2026 Feb 12","pmid":"41753126","title":"Interleukin-2 Receptor Antagonist Induction Therapy in Lung Transplantation-A Meta-Analysis of Reconstructed Time-to-Event Data.","journal":"Journal of clinical medicine"},{"date":"2026 Apr 15","pmid":"41747595","title":"Single-cell transcriptomic mendelian randomization and co-localization reveal immune-mediated regulatory mechanisms and drug targets in atopic dermatitis.","journal":"International immunopharmacology"},{"date":"2026 Jan","pmid":"41704136","title":"No Association of Sex or Racial Factors With Outcomes in Adult Intestine-Only Transplant: A United Network for Organ Sharing Database Analysis.","journal":"Experimental and clinical transplantation : official journal of the Middle East Society for Organ Transplantation"},{"date":"2012","pmid":"31643690","title":"Multiple Sclerosis Agents.","journal":""}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"withdrawn","companyName":"Hoffman-La Roche","companyId":"roche","modality":"Monoclonal antibody","firstApprovalDate":"1997","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"1997-12-10T00:00:00.000Z","mah":"HOFFMAN-LA ROCHE","brand_name_local":null,"application_number":""},{"country_code":"EU","regulator":"EMA","status":"pending","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"BR","regulator":"ANVISA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"MX","regulator":"COFEPRIS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AR","regulator":"ANMAT","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TR","regulator":"TITCK","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IN","regulator":"CDSCO","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TH","regulator":"FDA-TH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"MY","regulator":"NPRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"PH","regulator":"FDA-PH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"CO","regulator":"INVIMA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"ZA","regulator":"SAHPRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TW","regulator":"TFDA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"HK","regulator":"DH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T03:42:35.096110+00:00","fieldsConflicting":2,"overallConfidence":0.8},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}